Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03891758
Other study ID # BK1310-J03
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date April 1, 2019
Est. completion date August 10, 2020

Study information

Verified date November 2020
Source Mitsubishi Tanabe Pharma Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate immunogenicity of BK1310 for all antigens (anti-PRP, diphtheria toxin, pertussis, tetanus toxin, and polio virus), after 3 times of injection, when compared noninferiority with co-administration of ActHIB® and Tetrabik, as well as efficacy and safety, in healthy infants.


Recruitment information / eligibility

Status Completed
Enrollment 267
Est. completion date August 10, 2020
Est. primary completion date September 18, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 2 Months to 42 Months
Eligibility Inclusion Criteria: - Healthy infants aged =2 and <43 months at the first vaccination of the study drug (recommended: =2 and <7 months) - Written informed consent is obtained from a legal guardian (parent) Exclusion Criteria: - Possibility of anaphylaxis due to food or pharmaceuticals - With experience of Hib infection, diphtheria, pertussis, tetanus or acute poliomyelitis - With experience of Hib, diphteria, pertussis, tetanus or polio vaccination. - Participated in other studies within 12 weeks before obtaining consent - Considered to be not eligible by the principal investigators (sub-investigators) of the enrollment Additional screening criteria check may apply for qualification.

Study Design


Intervention

Biological:
DPT-IPV-Hib
0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
Hib vaccine
0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
DPT-IPV
0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.

Locations

Country Name City State
Japan Investigational Site Fukuoka-shi Fukuoka

Sponsors (2)

Lead Sponsor Collaborator
Mitsubishi Tanabe Pharma Corporation The Research Foundation for Microbial Diseases of Osaka University

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Antibody prevalence rate against anti-PRP with 1 µg/mL or higher, diphtheria toxin, pertussis, tetanus toxin, and polio virus 4 weeks after the primary immunization (Visit 4)
Secondary Anti-PRP antibody prevalence rate with 0.15 µg/mL or higher 4weeks after the primary immunization (Visit 4)
Secondary Geometric mean antibody titer of anti-PRP antibody 4weeks after the primary immunization (Visit 4)
Secondary Anti-PRP antibody prevalence rate with 1 µg/mL or higher 4weeks after the booster dose (Visit 6)
Secondary Geometric mean antibody titer of anti-PRP antibody 4weeks after the booster dose (Visit 6)
Secondary Geometric mean antibody titer against diphtheria toxin, pertussis, tetanus toxin, and polio virus 4weeks after the primary immunization (Visit 4)
Secondary Antibody prevalence rate against diphtheria toxin, pertussis, tetanus toxin, and polio virus 4weeks after the booster dose (Visit 6)
Secondary Geometric mean antibody titer against diphtheria toxin, pertussis, tetanus toxin, and polio virus 4weeks after the booster dose (Visit 6)
Secondary Adverse events and adverse reactions Through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Completed NCT00352963 - Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). Phase 3
Not yet recruiting NCT04056728 - A Phase IV Study to Assess the Safety of EupentaTM Inj Phase 4
Completed NCT00753649 - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Phase 4
Completed NCT02538211 - The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses N/A
Completed NCT01917357 - A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject Phase 3
Completed NCT01689324 - Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents Phase 1/Phase 2
Completed NCT01444781 - Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants Phase 3
Completed NCT01214889 - Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. Phase 3
Completed NCT00804284 - Database Surveillance Safety Study of PENTACEL® Vaccine N/A
Completed NCT00514709 - Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants Phase 3
Completed NCT00534833 - Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™ Phase 3
Completed NCT00379977 - Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age Phase 3
Completed NCT00772369 - Retrospective Survey of Safety of Fourth Dose Pentacel® in Children Phase 4
Completed NCT00879827 - Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants Phase 3
Completed NCT01457495 - Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly Phase 2
Completed NCT01267058 - Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults Phase 3
Completed NCT02853929 - Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Phase 4
Completed NCT02858440 - A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia Phase 3
Recruiting NCT06049940 - Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population Phase 3
Completed NCT00385255 - Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults Phase 3